Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Up 5.29%
As of Monday, September 21, Elicio Therapeutics, Inc.’s ELTX share price has surged by 5.29%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Down 5.03%
As of Wednesday, September 16, Elicio Therapeutics, Inc.’s ELTX share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Down 5.20%
As of Friday, September 04, Elicio Therapeutics, Inc.’s ELTX share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Michael Rose
Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Up 5.94%
As of Tuesday, August 04, Elicio Therapeutics, Inc.’s ELTX share price has surged by 5.94%, which has investors questioning if this is right time to sell.Michael Rose
Why Elicio Therapeutics, Inc.’s (ELTX) Stock Is Down 5.63%
As of Wednesday, July 15, Elicio Therapeutics, Inc.’s ELTX share price has dipped by 5.63%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | ELTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $50.2 | $269.5 | 15% |
|
| Shares Out (Mil) | 19.2 | 54.2 | 30% |
|
| Institutional Ownership | 43.0% | 93.0% | 18% |
|
| Float (Mil) | 19.2 | 42.1 | 28% |
|
| Beta | 1.86 | 0.95 | 90% |
|
| Avg Daily Volume (000s) | 443 | 609 | 55% |
|
| Price Change (52-week) |
(83.3%) | 54.5% | 6% |
|
| Growth | ELTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (20.3%) | (10.1%) | 20% |
|
| EPS (5yr) | (12.0%) | 15.4% | 20 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.0%) | (15.6%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.440) | ($1.950) | ($2.165) | |
| Month Ago EPS | ($0.440) | ($1.950) | ($2.165) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.498) | ($2.133) | ($2.637) | |
| Year/Year Chg | 3.0% | (24.5%) | 27.7% | |
| Financials | ELTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($38) | ($43) | 19% |
|
| EPS (TTM) | ($2.172) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($38) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $40 | $175 | 15% |
|
| Valuation | ELTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.31 | 2.60 | 80% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ELTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (124.4%) | (47.4%) | 4% |
|
| ROE | (774.6%) | (54.9%) | 0% |
|
| Liabilities to Assets | 74.7% | 29.3% | 70% |
|
| F-Score | 4 | 3 | 33% |
|
Elicio Therapeutics, Inc. did not pass any screens on 9/21/2026.
